Johnson & Johnson: Psychotic Disorders trials

The registry lists 57 Psychotic Disorders studies with Johnson & Johnson as lead sponsor. 1 are open to participants now and 13 have results posted.

Phase 1 9Phase 2 2Phase 3 23Phase 4 14No phase 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's DiseaseRecruitingNCT06540833Phase 2
• A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass SpectrometryTerminatedNCT02462473Phase 2Results posted
• A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or SchizophreniformCompletedNCT02431702Phase 3Results posted
• An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective DisordersCompletedNCT01855074Phase 4Results posted
• A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective DisorderCompletedNCT01193153Phase 3Results posted
• An Efficacy and Safety Study of Long Acting Injectable Risperidone and Oral Risperidone in Participants With Schizophrenia or Schizoaffective DisorderCompletedNCT00992407Phase 4Results posted
• Study to Measure the Safety of Paliperidone ER (Extended-release) in Patients With Liver DiseaseCompletedNCT00535145Phase 4Results posted
• Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.CompletedNCT00488319Phase 3Results posted
• Evaluation of Effectiveness and Safety of Flexible-dose Paliperidone Extended Release in Patients With Schizoaffective Disorder.CompletedNCT00412373Phase 3Results posted
• Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder.CompletedNCT00397033Phase 3Results posted
• Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With SchizophreniaCompletedNCT00299702Phase 4Results posted
• An Efficacy and Safety Study of Long-Term Risperidone Microspheres in Participants With SchizophreniaCompletedNCT00269919Phase 4Results posted
• A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early PsychosisCompletedNCT00246259Phase 4Results posted
• A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective DisorderCompletedNCT00216476Phase 3Results posted
• Sustainable Early Episode Clinic Study (SEEC)CompletedNCT03571685Not applicable
• Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric ParticipantsCompletedNCT02087579Phase 1
• Maintenance of Efficacy With Risperidone Long Acting Injectable (R-LAI) in Patients With Schizophrenia or Schizoaffective DisorderCompletedNCT01888107Phase 3
• An Epidemiological Study to Assess the Psychosocial and Symptomatic Remission and Community Integration Status in Patients With SchizophreniaCompletedNCT01309373
• A Drug Interaction Study of Valproic Acid and Paliperidone Extended-Release (ER) in Patients With Schizophrenia, Bipolar I Disorder, or Schizoaffective DisorderCompletedNCT01094249Phase 1
• Schizophrenia Treatment Adherence Investigation (STAI)CompletedNCT01001481
• A Pharmacokinetic Study of Risperidone and Topiramate Administered Alone and in Combination in Patients With Bipolar Disorder or Schizoaffective DisordersCompletedNCT00986336Phase 1
• Characterization of Intramuscular Injections of Risperidone 4 Week Long-acting Injectable (LAI) Formulation in the Buttock of Patients With SchizophreniaCompletedNCT00821600Phase 1
• As Study of the Pharmacokinetics of Paliperidone Extended-release and Risperidone Immediate-release FormulationsCompletedNCT00796185Phase 1
• A Safety and Pharmacokinetic Study of ER OROS Paliperidone in Pediatric Patients With Schizophrenia, Schizoaffective Disorder, or Schizophreniform DisorderCompletedNCT00796081Phase 1
• A Study of QT and QTc Intervals in Patients Administered Extended Release Paliperidone or QuetiapineCompletedNCT00791622Phase 1
• A Study of QT and QTc Intervals in Patients Administered Immediate Release PaliperidoneCompletedNCT00791349Phase 1
• Bioequivalence Study Comparing 2 Formulations for 4 mg Risperidone Tablet.CompletedNCT00645502Phase 1
• Medical Chart Review of Patients on Long-term Treatment With Long-acting Injectable RisperidoneCompletedNCT00644852
• A Long Term Study of Safety for Long Acting Injectable Risperidone in Patients With Schizophrenia or Schizoaffective Disorder.CompletedNCT00558298Phase 3
• An Efficacy and Safety Study of Long-acting Risperidone in Participants With Schizophrenia or Schizoaffective Disorders Who Are Receiving Psychiatric Home Care TreatmentCompletedNCT00526877Phase 4
• Study on the Safety and Effectiveness of Risperidone Treatment of Acute Psychotic PatientsTerminatedNCT00515489
• Study on the Safety of Risperidone on Obese or Overweight Patients With SchizophreniaTerminatedNCT00511628
• A Long-term Safety Study for Long-acting Injectable Risperidone in Schizophrenia or Schizoaffective Disorder Patients.CompletedNCT00495118Phase 3
• RiSPECT: Risperdal Safety Protocol Evaluation Consta Treatment, a Post Authorization Safety Survey to Obtain Information on the Safety and Efficacy of Risperidone When Used in Routine Clinical PracticeCompletedNCT00458367
• PROFILe3: Epidemiologic Survey in Patients With Schizophrenia or Schizoaffective DisordersCompletedNCT00399334
• A Study Comparing Three Strategies to Switch Patients With Schizophrenia or Schizoaffective Disorder to Risperidone After Unsuccessful Treatment With Olanzapine.CompletedNCT00378183Phase 4
• Treatment With Risperidone Long Acting Injectable (RLAI) in an Early Phase of PsychosisCompletedNCT00369239Phase 4
• A Study to Evaluate the Efficacy and Safety of Adjustable Doses of Extended-release (ER) Paliperidone Compared With Placebo, in Combination With Lithium or Valproate, to Treat Manic and Mixed Episodes in Patients With Bipolar I DisorderCompletedNCT00309686Phase 3
• A Study of How Long it Takes a Patient to Relapse After Switching From an Oral Antipsychotic to One of Two Doses of Long-acting Risperidone Injections in Patients With Schizophrenia or Schizoaffective DisorderCompletedNCT00297388Phase 3
• A Registry of Treatment Adherence for Patients With SchizophreniaCompletedNCT00283517
• A Study of the Effectiveness and Safety of Long-acting Injectable Risperidone Versus Placebo in the Treatment of Patients With SchizophreniaCompletedNCT00253136Phase 3
• A Comparison of Risperidone With Haloperidol in Patients With Schizophrenia and Schizoaffective DisorderCompletedNCT00253110Phase 4
• A Comparison of the Effectiveness and Safety of Injectable Risperidone With That of Risperidone Tablets in the Treatment of Patients With Chronic SchizophreniaCompletedNCT00249223Phase 3
• A Study of Risperidone in Combination With Lorazepam Compared With Standard Therapy for Emergency Treatment of Schizophrenic PatientsCompletedNCT00249171Phase 4
• A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol and Placebo in Patients With Chronic SchizophreniaCompletedNCT00249132Phase 3
• A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol in Patients With Chronic SchizophreniaCompletedNCT00249119Phase 3
• A Study of the Effectiveness and Safety of Risperidone in the Treatment of Adolescents With SchizophreniaCompletedNCT00246285Phase 3
• A Study of the Effectiveness and Safety of Topiramate in the Treatment of Patients With Bipolar DisorderCompletedNCT00240721Phase 3
• Evaluation of the Usefulness to Doctors of the Risperdal Consta Treatment Guidebook Over a Three-month Period During Which Adult Patients With Schizophrenia or Schizoaffective Disorder Are Switching From Daily Doses or Risperidone Tablets to Long-acting Risperidone by InjectionCompletedNCT00236548Phase 3
• A Study Comparing the Efficacy of Long-acting Injectable Risperidone and Olanzapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective DisorderCompletedNCT00236457Phase 3
• A Study of the Effects of Risperidone and Olanzapine on Blood Glucose (Sugar) in Patients With Schizophrenia or Schizoaffective DisorderCompletedNCT00236379Phase 4
• Evaluation of the Efficacy and Safety of Risperidone Injections Given Once a Month to Adults With Schizophrenia or Schizoaffective DisorderCompletedNCT00236353Phase 3
• A Study of Treatment Success in Changing From Olanzapine to Long-acting Injectable Risperidone (RISPERDAL® CONSTA™)CompletedNCT00216632Phase 4
• A Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia or Schizoaffective DisorderCompletedNCT00210691Phase 3
• Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective DisorderCompletedNCT00061802Phase 4
• A Study to Evaluate the Safety and Effectiveness of Topiramate Compared to Placebo in the Treatment of Patients With Bipolar I DisorderCompletedNCT00035802Phase 3
• A Study to Assess Safety and Tolerabiltiy Associated With a Switch From Oral Antipsychotic Medications to Long-acting Injectable Risperidone in Patients With Schizophrenia.CompletedNCT00034775Phase 3